+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Breast Cancer Screening Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Impact of COVID-19, Company Analysis

  • PDF Icon

    Report

  • 240 Pages
  • March 2022
  • Region: Asia Pacific
  • Renub Research
  • ID: 5562686
Asia Breast Cancer Screening Market is expected to reach USD 16.5 Billion by 2027. Breast cancer is a disease in which cells in breast tissue change and divide uncontrolled, typically resulting in a lump or mass. Remarkably, Asia is the world's largest continent comprising millions of the human population. Breast cancer is the most familiar type of cancer and the second leading cause of cancer-related deaths among women in Asia. Besides, the incidence of breast cancer in Asia varies widely across the continent, and cancer rates are increasing rapidly in parallel to socio-economic development.



Asia Breast Cancer Screening Industry is expected to expand at a CAGR of 8.5% during 2021-2027:


The major driving forces for expanding the breast cancer screening market in Asia are increasing breast cancer awareness, government and NGOs supporting breast cancer screening programs, and the aging population.

Nevertheless, critical threats for the breast cancer screening market in Asia are societal fear, misconceptions, and cultural barriers. Another major challenge being faced by almost all Asian countries is the non-availability of national-level screening programs; however, partial or regional screening programs are available in a few of Asian countries.

Mammogram Screening Leads Breast Cancer Screening in Asia:


Our report studies Breast Cancer Screening in Asia through Mammography Screening, MRI Screening, and Ultrasound Screening. As per our analysis, the mammogram is the leading method for breast cancer screening in Asian countries. Further, we have also made the market estimation that China, Japan, and Korea are the top three countries for breast cancer mammogram screening. Other Asian countries included in our study are India, Singapore, Malaysia, and Thailand for breast cancer mammogram screening.

China Holds Significant Dominance in Asia Breast Cancer Screening Market:


Our report studies the breast cancer screening market of Asian countries like India, China, Japan, Korea, Singapore, Thailand, and Malaysia. As per our analysis, China, Japan, and Korea are the top-most contributors to the breast cancer screening industry. In addition, China holds significant dominance in the Asia breast cancer screening market. Further, a prominent women population and domestic NGOs initiatives support China to become a leader in the Asian breast cancer screening market.

COVID-19 Impact on the Asia Breast Cancer Screening Industry:


Globally, over a billion people had been affected due to novel Coronavirus for the first time in 2020. The whole world had been facing problems in healthcare and the financial world during the pandemic era. Besides, most healthcare centers had reserved their team and resources for the treatment of COVID-19 patients, and due to this outbreak, women avoided diagnostics centers as lockdowns were imposed by governments across the world, declining the market. As per The report, Asia Breast Cancer Screening Market Size was USD 10.1 Billion in 2021 post recovery from the pandemic.

Key Players:


The companies contributing to the growth of the Asia breast cancer screening market include AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Sun Pharmaceutical Industries Ltd. The market players are considerably contributing to market growth by adopting various strategies, including new product launches, mergers and acquisitions, collaborations with the government, and technological advancements to stay competitive in the market.

This study titled Asia Breast Cancer Screening Market Forecast By Population Analysis (Mammography, MRI & Ultrasound),Market Analysis (Mammography Screening Market, MRI Screening Market, Ultrasound Screening Market), Countries (India, China, Japan, Korea, Singapore, Thailand and Malaysia), Company (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Sun Pharmaceutical Industries Ltd.) provides a detailed analysis of Asia Breast Cancer Screening Industry.

Asia Breast Cancer Screening Population Analysis has been covered from 2 viewpoints:


1. Mammography Screening Population
2. MRI & Ultrasound Screening Population

Asia Breast Cancer Screening Market Analysis has been covered from 3 viewpoints:


1. Mammography Screening Market
2. MRI Screening Market
3. Ultrasound Screening Market

Countries covered in Asia Breast Cancer Screening Market Analysis have been covered from 7 viewpoints:


1. India
2. China
3. Japan
4. Korea
5. Singapore
6. Thailand
7. Malaysia

Company Insights:


  • Overview
  • Recent Development
  • Revenue

Company Analysis:


1. AstraZeneca
2. Novartis
3. Sanofi
4. Pfizer
5. Bayer AG
6. GlaxoSmithKline plc
7. Hoffmann-La Roche Ltd.
8. Sun Pharmaceutical Industries Ltd
Frequently Asked Questions about the Asia Breast Cancer Screening Market

What is the estimated value of the Asia Breast Cancer Screening Market?

The Asia Breast Cancer Screening Market was estimated to be valued at $10.1 Billion in 2021.

What is the growth rate of the Asia Breast Cancer Screening Market?

The growth rate of the Asia Breast Cancer Screening Market is 8.5%, with an estimated value of $16.5 Billion by 2027.

What is the forecasted size of the Asia Breast Cancer Screening Market?

The Asia Breast Cancer Screening Market is estimated to be worth $16.5 Billion by 2027.

Who are the key companies in the Asia Breast Cancer Screening Market?

Key companies in the Asia Breast Cancer Screening Market include AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline plc, Hoffmann and Sun Pharmaceutical Industries Ltd.

Table of Contents

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Asia Breast Cancer Screening Population Analysis
5.1 Mammography Screening Population
5.2 MRI & Ultrasound Screening Population
6. Asia Breast Cancer Screening Market Analysis
6.1 Breast Cancer Screening Market
6.1.1 Mammography Screening Market
6.1.2 MRI Screening Market
6.1.3 Ultrasound Screening Market
7. Population Share - Asia Breast Cancer Screening
7.1 Mammography Screening Population Share
7.2 MRI & Ultrasound Screening Population Share
8. Market Share - Asia Breast Cancer Screening Analysis
8.1 Asia Breast Cancer Screening Market Share
8.2 Mammography Screening Market Share
8.3 MRI Screening Market Share
8.4 Ultrasound Screening Market Share
9. India
9.1 India Breast Cancer Mammography Screening Population
9.2 India Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
9.3 India Breast Cancer Screening Market
9.3.1 Mammography Screening Market
9.3.2 Magnetic Resonance Imaging (MRI) Screening Market
9.3.3 Ultrasound Screening Market
10. China
10.1 China Breast Cancer Mammography Screening Population
10.2 China Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
10.3 China Breast Cancer Screening Market & Forecast
10.3.1 Mammography Screening Market
10.3.2 Magnetic Resonance Imaging (MRI) Screening Market
10.3.3 Ultrasound Screening Market
11. Japan
11.1 Japan Breast Cancer Mammography Screening Population
11.2 Japan Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
11.3 Japan Breast Cancer Screening Market
11.3.1 Mammography Screening Market
11.3.2 Magnetic Resonance Imaging (MRI) Screening Market
11.3.3 Ultrasound Screening Market
12. Korea
12.1 Korea Breast Cancer Mammography Screening Population
12.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
12.3 Korea Breast Cancer Screening Market
12.3.1 Mammography Screening Market
12.3.2 Magnetic Resonance Imaging (MRI) Screening Market
12.3.3 Ultrasound Screening Market
13. Singapore
13.1 Singapore Breast Cancer Mammography Screening Population
13.2 Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
13.3 Singapore Breast Cancer Screening Market
13.3.1 Mammography Screening Market
13.3.2 Magnetic Resonance Imaging (MRI) Screening Market
13.3.3 Ultrasound Screening Market
14. Thailand
14.1 Thailand Breast Cancer Mammography Screening Population
14.2 Thailand Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
14.3 Thailand Breast Cancer Screening Market
14.3.1 Mammography Screening Market
14.3.2 Magnetic Resonance Imaging (MRI) Screening Market
14.3.3 Ultrasound Screening Market
15. Malaysia
15.1 Malaysia Breast Cancer Mammography Screening Population
15.2 Malaysia Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
15.3 Malaysia Breast Cancer Screening Market
15.3.1 Mammography Screening Market
15.3.2 Magnetic Resonance Imaging (MRI) Screening Market
15.3.3 Malaysia Breast Cancer Ultrasound Screening Market
16. Porter's Five Forces
16.1 Overview
16.2 Bargaining Power of Buyers
16.3 Bargaining Power of Suppliers
16.4 Degree of Competition
16.5 Threat of New Entrants
16.6 Threat of Substitutes
17. Company Analysis
17.1 AstraZeneca
17.1.1 Overview
17.1.2 Recent Development
17.1.3 Revenue
17.2 Novartis
17.2.1 Overview
17.2.2 Recent Development
17.2.3 Revenue
17.3 Sanofi
17.3.1 Overview
17.3.2 Recent Development
17.3.3 Revenue
17.4 Pfizer
17.4.1 Overview
17.4.2 Recent Development
17.4.3 Revenue
17.5 Bayer AG
17.5.1 Overview
17.5.2 Recent Development
17.5.3 Revenue
17.6 GlaxoSmithKline plc
17.6.1 Overview
17.6.2 Recent Development
17.6.3 Revenue
17.7 Hoffmann-La Roche Ltd.
17.7.1 Overview
17.7.2 Recent Development
17.7.3 Revenue
17.8 Sun Pharmaceutical Industries Ltd
17.8.1 Overview
17.8.2 Recent Development
17.8.3 Revenue
List Of Figures:
Figure 01: Asia - Breast Cancer Mammography Screening Population (Million), 2016 - 2021
Figure 02: Asia - Forecast for Breast Cancer Mammography Screening Population (Million), 2022 - 2027
Figure 03: Asia - Breast Cancer MRI & Ultrasound Screening Population (Thousand), 2016 - 2021
Figure 04: Asia - Forecast for Breast Cancer MRI & Ultrasound Screening Population (Thousand), 2022 - 2027
Figure 05: Asia - Breast Cancer Mammography Screening Market (Million US$), 2016 - 2021
Figure 06: Asia - Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 - 2027
Figure 07: Asia - Breast Cancer MRI Screening Market (Million US$), 2016 - 2021
Figure 08: Asia - Forecast for Breast Cancer MRI Screening Market (Million US$), 2022 - 2027
Figure 09: Asia - Breast Cancer Ultrasound Screening Market (Million US$), 2016 - 2021
Figure 10: Asia - Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 - 2027
Figure 11: India - Breast Cancer Mammography Screening Population (Thousand), 2016 - 2021
Figure 12: India - Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 - 2027
Figure 13: India - Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2016 - 2021
Figure 14: India - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 - 2027
Figure 15: India - Breast Cancer Mammography Screening Market (Million US$), 2016 - 2021
Figure 16: India - Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 - 2027
Figure 17: India - Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2016 - 2021
Figure 18: India - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 - 2027
Figure 19: India - Breast Cancer Ultrasound Screening Market (Million US$), 2016 - 2021
Figure 20: India - Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 - 2027
Figure 21: China - Breast Cancer Mammography Screening Population (Thousand), 2016 - 2021
Figure 22: China - Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 - 2027
Figure 23: China - Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2016 - 2021
Figure 24: China - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 - 2027
Figure 25: China - Breast Cancer Mammography Screening Market (Million US$), 2016 - 2021
Figure 26: China - Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 - 2027
Figure 27: China - Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2016 - 2021
Figure 28: China - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 - 2027
Figure 29: China - Breast Cancer Ultrasound Screening Market (Million US$), 2016 - 2021
Figure 30: China - Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 - 2027
Figure 31: Japan - Breast Cancer Mammography Screening Population (Thousand), 2016 - 2021
Figure 32: Japan - Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 - 2027
Figure 33: Japan - Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2016 - 2021
Figure 34: Japan - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 - 2027
Figure 35: Japan - Breast Cancer Mammography Screening Market (Million US$), 2016 - 2021
Figure 36: Japan - Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 - 2027
Figure 37: Japan - Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2016 - 2021
Figure 38: Japan - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 - 2027
Figure 39: Japan - Breast Cancer Ultrasound Screening Market (Million US$), 2016 - 2021
Figure 40: Japan - Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 - 2027
Figure 41: Korea - Breast Cancer Mammography Screening Population (Thousand), 2016 - 2021
Figure 42: Korea - Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 - 2027
Figure 43: Korea - Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2016 - 2021
Figure 44: Korea - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 - 2027
Figure 45: Korea - Breast Cancer Mammography Screening Market (Million US$), 2016 - 2021
Figure 46: Korea - Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 - 2027
Figure 47: Korea - Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2016 - 2021
Figure 48: Korea - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 - 2027
Figure 49: Korea - Breast Cancer Ultrasound Screening Market (Million US$), 2016 - 2021
Figure 50: Korea - Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 - 2027
Figure 51: Singapore - Breast Cancer Mammography Screening Population (Thousand), 2016 - 2021
Figure 52: Singapore - Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 - 2027
Figure 53: Singapore - Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2016 - 2021
Figure 54: Singapore - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 - 2027
Figure 55: Singapore - Breast Cancer Mammography Screening Market (Million US$), 2016 - 2021
Figure 56: Singapore - Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 - 2027
Figure 57: Singapore - Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2016 - 2021
Figure 58: Singapore - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 - 2027
Figure 59: Singapore - Breast Cancer Ultrasound Screening Market (Million US$), 2016 - 2021
Figure 60: Singapore - Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 - 2027
Figure 61: Thailand - Breast Cancer Mammography Screening Population (Thousand), 2016 - 2021
Figure 62: Thailand - Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 - 2027
Figure 63: Thailand - Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2016 - 2021
Figure 64: Thailand - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 - 2027
Figure 65: Thailand - Breast Cancer Mammography Screening Market (Million US$), 2016 - 2021
Figure 66: Thailand - Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 - 2027
Figure 67: Thailand - Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2016 - 2021
Figure 68: Thailand - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 - 2027
Figure 69: Thailand - Breast Cancer Ultrasound Screening Market (Million US$), 2016 - 2021
Figure 70: Thailand - Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 - 2027
Figure 71: Malaysia - Breast Cancer Mammography Screening Population (Thousand), 2016 - 2021
Figure 72: Malaysia - Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 - 2027
Figure 73: Malaysia - Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2016 - 2021
Figure 74: Malaysia - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 - 2027
Figure 75: Malaysia - Breast Cancer Mammography Screening Market (Million US$), 2016 - 2021
Figure 76: Malaysia - Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 - 2027
Figure 77: Malaysia - Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2016 - 2021
Figure 78: Malaysia - Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 - 2027
Figure 79: Malaysia - Breast Cancer Ultrasound Screening Market (Million US$), 2016 - 2021
Figure 80: Malaysia - Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 - 2027
Figure 81: AstraZeneca - Global Revenue (Million US$), 2016 - 2021
Figure 82: AstraZeneca - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 83: Novartis - Global Revenue (Million US$), 2016 - 2021
Figure 84: Novartis - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 85: Sanofi - Global Revenue (Million US$), 2016 - 2021
Figure 86: Sanofi - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 87: Pfizer - Global Revenue (Million US$), 2016 - 2021
Figure 88: Pfizer - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 89: Bayer AG - Global Revenue (Million US$), 2016 - 2021
Figure 90: Bayer AG - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 91: GlaxoSmithKline plc - Global Revenue (Million US$), 2016 - 2021
Figure 92: GlaxoSmithKline plc - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 93: Hoffmann-La Roche Ltd. - Global Revenue (Million US$), 2016 - 2021
Figure 94: Hoffmann-La Roche Ltd. - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure 95: Sun Pharmaceutical Industries Ltd - Global Revenue (Million US$), 2016 - 2021
Figure 96: Sun Pharmaceutical Industries Ltd - Forecast for Global Revenue (Million US$), 2022 - 2027
List Of Tables:
Table 01: Asia - Mammography Screening Population Share by Country (Percent), 2016 - 2021
Table 02: Asia - Forecast for Mammography Screening Population Share by Country (Percent), 2022 - 2027
Table 03: Asia - MRI & Ultrasound Screening Population Share by Country (Percent), 2016 - 2021
Table 04: Asia - Forecast for MRI & Ultrasound Screening Population Share by Country (Percent), 2022 - 2027
Table 05: Asia - Breast Cancer Screening Market Share by Country (Percent), 2016 - 2021
Table 06: Asia - Forecast for Breast Cancer Screening Market Share by Country (Percent), 2022 - 2027
Table 07: Asia - Mammography Screening Market Share by Country (Percent), 2016 - 2021
Table 08: Asia - Forecast for Mammography Screening Market Share by Country (Percent), 2022 - 2027
Table 09: Asia - MRI Screening Market Share by Country (Percent), 2016 - 2021
Table 10: Asia - Forecast for MRI Screening Market Share by Country (Percent), 2022 - 2027
Table 11: Asia - Ultrasound Screening Market Share by Country (Percent), 2016 - 2021
Table 12: Asia - Forecast for Ultrasound Screening Market Share by Country (Percent), 2022 - 2027

Companies Mentioned

  • AstraZeneca
  • Novartis
  • Sanofi
  • Pfizer
  • Bayer AG
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Ltd.
  • Sun Pharmaceutical Industries Ltd

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...